Preliminary Analysis Of A Us Phase Ii Study Of The Safety And Tolerability Of Proxalutamide (Gt0918) In Subjects With Mcrpc Who Had Progressed On Either Abiraterone (Abi) Or Enzalutamide (Enza).
JOURNAL OF CLINICAL ONCOLOGY(2021)
摘要
99Background: GT0918, an androgen receptor (AR) antagonist, is a new chemical entity with reduced drug accumulation in the CNS. In a phase I dose escalation trial (NCT02826772), GT0918 was well tol...
更多查看译文
关键词
Androgen Receptor
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要